CNRL in silico exercise to determine the capabilities of network laboratories to detect triple reassortant swine origin influenza A(H3N2) viruses
Following the emergence of swine influenza A(H3N2) variant (v) viruses with sporadic human infections in North America, the Community Network of Reference Laboratories (CNRL) and the Animal Health and Veterinary Laboratories Agency completed an exercise to assess the CNRL’s capability to detect novel reassortant and circulating triple reassortant swine viruses (TRA) in humans.
Influenza A(H3N2)v laboratory detection questionnaire results
Following the emergence of swine influenza A(H3N2) variant (v) viruses with sporadic human infections in North America, ECDC and the Community Network of Reference Laboratories (CNRL) disseminated a questionnaire to explore the RT-PCR capability of influenza reference laboratories in EU/EEA countries to detect A(H3N2)v viruses in their day-to-day diagnostics and to subtype them as swine-origin variant viruses.
Survey of National Reference Laboratory capacity for six FWD in EU/EEA countries
In 2009, a survey was conducted to form a picture of the availability and scope of services offered by National Reference Laboratories in EU and EEA countries with respect to six priority food and waterborne pathogens: Campylobacter, Listeria, Salmonella, Shigella, Shiga toxin/verotoxin–producing Escherichia coli (STEC/VTEC) and Yersinia.
Laboratory capability for molecular detection and confirmation of novel coronavirus in Europe, November 2012.
Palm, D., Pereyaslov, D., Vaz, J., Broberg, E., Zeller, H., Gross, D., Brown, C., Struelens, M., on behalf of the Joint ECDC-WHO Regional Office for Europe Novel Coronavirus Laboratory Survey participants, ECDC National Microbiology Focal Points, WHO European Region EuroFlu Network European Network for Diagnostics of Imported" Viral Diseases (ENIVD)."
EU Laboratory Capability Monitoring System (EULabCap): Report on 2015 survey of EU/EEA country capabilities and capacities
This report aims to help policymakers identify possible areas for action and to evaluate the impact of capacity strengthening activities and health system reforms.
Gap analysis on securing diphtheria diagnostic capacity and diphtheria antitoxin availability in the EU/EEA
This gap analysis demonstrated that there are significant gaps in diphtheria diagnostic capacity within the EU/EEA, with only six Member States fulfilling the minimum criteria in terms of surveillance, specialised laboratory diagnostics and expertise.
European laboratories move forward towards stronger epidemic readiness for infectious disease threats.
The latest EULabCap data on assessing the public health laboratory capacities among 30 EU and EEA countries in 2016 reveal continuous improvement in reducing inequalities, with ten more countries reaching fair to high capability levels over the 4 years of monitoring.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
External quality assessment scheme for Bordetella pertussis serology 2016
This external quality assessment (EQA) to assess the ability of national reference laboratories from EU/EEA Member States to correctly perform laboratory serodiagnostic tests for pertussis was a collaborative study organised from February to April 2016.
Rapid risk assessment: Candida auris in healthcare settings – Europe
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries